BioCentury
ARTICLE | Clinical News

Trumenba regulatory update

May 30, 2016 7:00 AM UTC

EMA accepted for review an MAA from Pfizer for Trumenba to prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B in individuals ages >=10. In 2014, FDA granted accelerate...